CYP1A2 and ADORA2A Genotypes and Endurance Performance.

NCT06547307 | Recruiting

• 1 other identifier: MasarykU
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this randomized, double-blind, placebo-controlled experiment will be to assess the potential effect of the selected gene polymorphism (CYP1A2, ADORA2A) on performance after caffeine ingestion.

Conditions

Healthy

Keywords

endurance; genotype; caffeine; ergogenic effect

Outcome Measures

Primary Outcomes (1)

• Efficacy of caffeine to improve endurance performance (time to complete 10 km trial)

  To determine if caffeine intake improves endurance performance compared to placebo. Efficacy of caffeine doses (2 mg/kg and 4 mg/kg) to shorten the time needed to complete the 10 km time trial.

  2 Hours

Secondary Outcomes (1)

• Caffeine ingestion and genotype interaction

  1 day

Study Arms (3)

Caffeine 2 mg

ACTIVE COMPARATOR

To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform one exercise test (10 km cycling time trial).

Dietary Supplement: Caffeine 2 mg

Caffeine 4 mg

ACTIVE COMPARATOR

To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform one exercise test (10 km cycling time trial).

Dietary Supplement: Caffeine 4 mg

Placebo

PLACEBO COMPARATOR

To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform one exercise test (10 km cycling time trial).

Dietary Supplement: Caffeine 0 mg

Interventions

Caffeine 2 mg DIETARY_SUPPLEMENT

To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.

Caffeine 2 mg

Caffeine 4 mg DIETARY_SUPPLEMENT

To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.

Caffeine 4 mg

Caffeine 0 mg DIETARY_SUPPLEMENT

To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.

Placebo

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• healthy person
• any training status
• within age limits
• without contraindications to perform the test on a bicycle trainer
• No contraindications to caffeine intake

You may not qualify if:

• Pregnancy
• Breast feeding
• Cardiovascular disease
• Hypertension
• Liver disease in the previous two months
• Taking drugs that can affect liver function
• Illness in the period of 14 days before the start of the research
• Use of caffeine during research

Sponsors & Collaborators

• Masaryk University: lead

Study Sites (1)

Masaryk University

Brno, Czechia

RECRUITING

MeSH Terms

Interventions

Caffeine

Intervention Hierarchy (Ancestors)

Xanthines; Alkaloids; Heterocyclic Compounds; Purinones; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Officials

• Lucie Lipková

  Masaryk University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Dominik Puda

CONTACT

+420724587249; dominik.puda@fsps.muni.cz

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 1, 2024
• First Posted: August 9, 2024
• Study Start: August 1, 2024
• Primary Completion: January 1, 2025
• Study Completion: March 1, 2025
• Last Updated: August 9, 2024

Record last verified: 2024-08

Locations

CZ (1)